Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric Huatanzhike granules plus routine therapy for mild to moderate COVID-19
ChiCTR2000030022Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Feb 2020
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Huatanzhike in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoints: Time to SARS-CoV-2 nucleic acid negativity in respiratory secretions, Lung CT inflammation absorption and 1 more. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
Huatanzhike
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000030022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030022.